AKTS Aktis Oncology, Inc.

bearish track record → $20.43 +0.51 (+2.6%)
Mkt Cap $1B 52wk $14.72 - $29.16 15d ago
≠
We disagree with Wall Street. Analyst consensus: bullish. Our position: bearish. See factor model below for why.
Factor divergence: DIVERGENCE: insider_activity, price_momentum bullish vs estimate_revisions, analyst_revisions bearis
Est. revisions: -37.1%
Backed by structured data (insider trades, analyst ratings, or filings)
Factor Model (net -2.0)

Factor Model

net -2.0 5.4 / 10
Est. Revisions
-1.0
Insider Activity
+0.5
Momentum
+0.7
Analyst Rev.
-1.0
Narrative Gap
+0.0

AKTS short interest jumps 10% to 16.2% float

Watch: Monitor upcoming clinical or FDA news that could shift bearish sentiment that currently drives elevated short pressure.

Short interest in Aktis Oncology rose nearly 10% to 2.57 million shares, representing 16.2% of the float. Days to cover stand at 8.1, signaling persistent bearish bets despite prior insider buying and strong cash reserves. The stock trades 11% below its 52-week high amid a downtrend and negative operating margins above -900%.

Growing short interest indicates mounting market skepticism against recent insider buying and analyst bullishness, raising short-term downside risk.

Evidence

15d ago Short interest at 16.2% of float, up 10%
34d ago William Blair init AKTS: Outperform
49d ago Insider buy by GADICKE ANSBERT S. (AKTS): $20,029,986
49d ago Insider buy by FOLEY TODD (AKTS): $4,191,660
49d ago Insider buy by KIM HELEN SUSAN (AKTS): $15,030,000
49d ago Insider buy by MPM BIOVENTURES 2018, L.P. (AKTS): $20,029,986
49d ago Insider buy by ECOR1 CAPITAL, L.L.C. (AKTS): $39,999,996
49d ago Insider buy by VIDA VENTURES II, L.L.C (AKTS): $15,030,000
1 older signals
50d ago BofA Lowers its Price Target on Pfizer (PFE) to $26 from $27
Fundamentals & Data ▾
Aktis Oncology, Inc. Healthcare · Biotechnology
Mkt Cap
$1B
52w Range
$14.72 - $29.16
Short Interest
2.6M 16.25%
Days to Cover
8.1 +11%
Technicals mixed
vs 20d MA
+3.4%
from 52w Hi
-9.8%
Vol (20d)
52%
1w return
+7.7%
1m return
-0.8%
Vol ratio
0.9x
Insiders
buying 6B / 0S
Analysts
bullish 1 up / 0 down
EPS Estimate
$-0.48 -37.1% 30d 0up / 2dn
Est. Dispersion
29% 3 analysts
Analyst Target
$32 $30 - $34
Financials
Revenue
$3M
FCF
$-26M
Op Margin
-704%
Momentum: accelerating
Track Record (0/1 correct) ▾

Direction History

0/1 correct at 5 days
2026-05-18 bearish +10.6% ✗
Full track record across all stocks →
9 signals · latest 15d ago

Keep reading the market

Direction shifts, insider clusters, filing red flags, and earnings call changes stay published on the site.

All stocks → Track record → How it works →